Edwards Lifesciences Corp

Listed Company

EWCIK 0001099800NYSELarge AcceleratedOrthopedic, Prosthetic & Surgical Appliances & SuppliesDelawareFY ends Dec 31

Period

FY 2025

Revenue

$6.07B

Net Income

$1.07B

Total Assets

$13.70B

Equity

$10.34B

Shares Out

580.80M

Op. Cash Flow

$1.60B

Business

Edwards Lifesciences Corp develops and commercializes medical technologies for structural heart disease, focusing on surgical and transcatheter therapies to improve patient outcomes. The company offers transcatheter aortic valves (SAPIEN family), transcatheter mitral and tricuspid repair and replacement systems (including PASCAL Precision, EVOQUE, Cardioband), and surgical tissue heart valves and repair devices (RESILIA tissue, INSPIRIS, MITRIS, annuloplasty rings, conduits). Its business is organized into three product groups: Transcatheter Aortic Valve Replacement (TAVR), Transcatheter Mitral and Tricuspid Therapies (TMTT), and Surgical Structural Heart. Edwards sells worldwide through direct sales forces and independent distributors across approximately 100 countries, with tailored sales, clinical education, and hospital partnerships.

Summary from filing dated 2025-02-28

Financials

Consolidated Statement of Income

Year Ended · In millions, except per-share amounts

Concept	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31
Net sales	6,068	5,440	5,010	4,464	5,233
Cost of sales	1,334	1,118	978	724	1,249
Gross profit	4,733	4,322	4,032	3,740	3,984
Selling, general, and administrative expenses	2,085	1,789	1,583	1,358	1,494
Research and development expenses	1,079	1,053	963	844	903
Intellectual property agreement and certain litigation expenses (Note 3)	325	40	204	16	21
Change in fair value of contingent consideration liabilities (Note 13)	−13	0	−26	−36	−124
Restructuring charges, separation costs, and other (Note 4)	19	61	0	—	—
Intangible assets impairment charges	40	0	0	—	—
Other operating income	−67	−300,000	0	0	—
Operating income	1,264	1,379	1,309	1,498	1,690
Interest expense	20	20	18	19	—
Interest income	−169	−120	−67	−36	−17
Loss on impairment	147	0	0	—	—
Other non-operating income, net (Note 18)	−7	−69	−14	−5	−13
Income from continuing operations before provision for income taxes	1,273	1,548	1,372	1,520	1,702
Provision for income taxes (Note 19)	217	152	152	196	199
Net income from continuing operations	1,056	1,396	1,220	1,324	—
Income from discontinued operations, net of tax	13	2,774	179	198	—
Net income	1,069	4,170	1,399	1,522	1,503
Less: Net loss attributable to noncontrolling interest	−4	−5	−3	0	0
Net income attributable to Edwards Lifesciences Corporation.	1,074	4,175	1,402	1,522	1,503
Continuing operations (in dollars per share)	1.81	2.34	2.02	2.14	—
Discontinued operations (in dollars per share)	0.03	4.64	0.29	0.32	—
Basic earnings per share (in dollars per share)	1.84	6.98	2.31	2.46	2.41
Continuing operations (in dollars per share)	1.81	2.34	2.01	2.12	—
Discontinued operations (in dollars per share)	0.02	4.63	0.29	0.32	—
Diluted earnings per share (in dollars per share)	1.83	6.97	2.3	2.44	2.38
Basic (in shares)	585	598	607	619	623
Diluted (in shares)	586	599	609	624	631

Consolidated Balance Sheet

As of · In millions, except per-share amounts

Concept	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31
Cash and cash equivalents	2,938	3,045	1,132	769	863
Short-term investments (Note 8)	1,288	931	501	446	604
Accounts receivable, net of allowances of $15.0 and $11.6, respectively	660	609	772	643	582
Other receivables	253	118	57	—	—
Inventories (Note 6)	1,126	1,087	904	876	727
Prepaid expenses	135	121	129	110	85
Other current assets	339	348	225	196	237
Current assets of discontinued operations (Note 5)	0	27	318	—	—
Total current assets	6,739	6,285	4,036	3,096	3,181
Long-term investments (Note 8)	279	308	584	1,239	1,834
Property, plant, and equipment, net (Note 6)	1,812	1,686	1,591	1,633	1,547
Operating lease right-of-use assets (Note 7)	103	98	84	92	92
Goodwill (Note 11)	1,769	1,777	1,145	1,065	1,168
Other intangible assets, net (Note 11)	1,128	1,177	399	285	324
Deferred income taxes	1,138	992	749	484	247
Other assets	730	722	463	299	111
Non-current assets of discontinued operations (Note 5)	0	11	311	—	—
Total assets	13,697	13,055	9,363	8,293	8,503
Accounts payable	228	197	187	202	205
Accrued and other liabilities (Note 6)	1,562	1,282	856	795	802
Operating lease liabilities (Note 7)	25	23	23	26	26
Current liabilities of discontinued operations (Note 5)	0	2	130	—	—
Total current liabilities	1,814	1,505	1,195	1,022	1,032
Long-term debt (Note 12)	598	598	597	596	596
Operating lease liabilities (Note 7)	83	79	65	70	69
Uncertain tax positions (Note 19)	503	385	335	268	259
Litigation settlement accrual	0	53	94	143	191
Other liabilities	362	373	251	218	267
Total liabilities	3,360	2,992	2,644	2,486	2,667
Commitments and contingencies (Note 7, Note 12, and Note 20)	—	—	—	—	—
Preferred stock, $0.01 par value, authorized 50.0 shares, no shares outstanding	0	0	0	0	0
Common stock, $1.00 par value, 1,050.0 shares authorized, 658.7 and 654.8 shares issued, and 580.7 and 588.6 shares outstanding, respectively	659	655	651	646	642
Additional paid-in capital	2,768	2,613	2,274	1,969	1,700
Retained earnings	14,241	13,167	8,992	7,590	6,068
Accumulated other comprehensive loss (Note 17)	−238	−245	−243	−255	−158
Treasury stock, at cost, 78.0 and 66.2 shares, respectively	−7,092	−6,192	−5,025	−4,144	−2,417
Total Edwards Lifesciences Corporation stockholders' equity	10,338	9,998	6,650	5,807	5,836
Noncontrolling interest (Note 9)	0	65	69	0	—
Total stockholders' equity	10,338	10,063	6,719	5,807	5,836
Total liabilities and equity	13,697	13,055	9,363	8,293	8,503

Consolidated Statement of Cash Flows

Year Ended · In millions, except per-share amounts

Concept	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31
Depreciation and amortization	157	155	145	140	135
Non-cash operating lease cost	26	28	28	27	29
Stock-based compensation (Note 2 and Note 16)	158	162	139	127	109
Gain on sale of product groups (Note 5)	−34	−3,348	0	0	—
Deferred income taxes	−118	−323	−272	−255	−41
Gain on remeasurement of previously held equity interest upon acquisition (Note 10)	0	−55	0	0	—
Loss on impairment and intangible assets impairment charges (Note 11 and Note 9)	187	0	0	55	4
Other	8	13	9	8	9
Accounts and other receivables, net	−23	121	−141	−84	−91
Inventories	51	−256	−289	−213	19
Prepaid expenses and other current assets	−24	23	−82	100,000	8
Accounts payable and accrued liabilities	395	90	146	−21	195
Intellectual property agreement accrual	−77	−37	−33	−45	−29
Income taxes	−142	−187	−6	−6	62
Long-term prepaid royalties (Note 3)	8	8	−110	0	0
Other	−35	−21	−12	−52	−19
Net cash provided by operating activities	1,595	542	896	1,218	1,732
Capital expenditures	−260	−252	−253	−245	−326
Investments in unconsolidated entities (Note 8)	−65	−60	−16	—	—
Purchases of held-to-maturity investments (Note 8)	−43	−46	−66	−354	−250
Proceeds from sales and maturities of held-to-maturity investments (Note 8)	62	58	98	420	138
Purchases of available-for-sale investments (Note 8)	−3,092	−900	−9	−316	−1,629
Proceeds from sales and maturities of available-for-sale investments (Note 8)	2,816	800	618	940	391
Business combinations, net of cash (Note 10)	0	−1,062	−95	0	0
Payments for acquisition options (Note 9)	−25	−46	−30	−110	−13
Issuances of notes receivable	−141	−63	−63	−52	−5
Investments in intangible assets	0	−30	−13	−20	−4
Payment for working capital adjustment and proceeds from sale of Critical Care (Note 5)	−36	3,927	0	—	—
Proceeds from sale of non-core product group (Note 5)	79	0	0	0	—
Other	−7	−13	3	−29	−44
Net cash (used in) provided by investing activities	−713	2,313	174	252	−1,723
Purchase of remaining noncontrolling interest in subsidiary (Note 9)	−234	0	0	—	—
Purchases of treasury stock	−893	−1,159	−880	−1,727	−513
Proceeds from stock plans	174	180	170	146	159
Other	−4	−3	−1	−4	−300,000
Net cash used in financing activities	−957	−983	−711	−1,585	−356
Effect of currency exchange rate changes on cash, cash equivalents, and restricted cash	−45	39	17	19	14
Net (decrease) increase in cash, cash equivalents, and restricted cash	−119	1,911	375	−95	−333

Filings

Filing historySign up free to browse every 10-K, 10-Q, 8-K, and proxy this filer has submitted to the SEC.Sign up free · Upgrade to Pro

Material Events

Material EventsTrack every 8-K filing and material event — AI-summarized, timelined, and alertable.Sign up free · Upgrade to Pro

Insiders

Insider ActivitySee executive buy/sell windows and insider trade activity over rolling 30/90/365-day windows.Sign up free · Upgrade to Pro

Institutional Holders

Institutional HoldersSee which funds hold this stock and track position changes quarter over quarter.Sign up free · Upgrade to Pro